*Storage: Inert atmosphere,Room Temperature.
*Shipping:
Cinacalcet hydrochloride (AMG-073 hydrochloride) is an orally active, allosteric agonist of the Ca receptor (CaR), used for treating cardiovascular diseases.
Synonyms: AMG-073 hydrochloride;Cinacalcet (hydrochloride);Mimpara
4.5
*For Research Use Only !
Change View
Size | Price | USA Stock *0-1 Day | Global Stock *5-7 Days | In Stock |
5mg | łÇʶÊÊ | In Stock | In Stock | Login |
10mg | łÇ˶ÊÊ | In Stock | In Stock | Login |
50mg | łÇÿ¶ÊÊ | In Stock | In Stock | Login |
100mg | łÇî¶ÊÊ | In Stock | In Stock | Login |
250mg | łËó¶ÊÊ | In Stock | In Stock | Login |
1g | łòʶÊÊ | In Stock | In Stock | Login |
5g | łËËó¶ÊÊ | In Stock | In Stock | Login |
25g | łóÇʶÊÊ | In Stock | In Stock | Login |
100g | łËòďǶÊÊ | In Stock | In Stock | Login |
Please Login or Create an Account to: See VIP prices and availability
łÇʶÊÊ
łÇ˶ÊÊ
łÇÿ¶ÊÊ
łÇî¶ÊÊ
łËó¶ÊÊ
łòʶÊÊ
łËËó¶ÊÊ
łóÇʶÊÊ
łËòďǶÊÊ
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 364782-34-3 |
Formula : | C22H23ClF3N |
M.W : | 393.87 |
SMILES Code : | FC(C1=CC(CCCN[C@@H](C2=C3C=CC=CC3=CC=C2)C)=CC=C1)(F)F.[H]Cl |
Synonyms : |
AMG-073 hydrochloride;Cinacalcet (hydrochloride);Mimpara
|
InChI Key : | QANQWUQOEJZMLL-PKLMIRHRSA-N |
Pubchem ID : | 156418 |
GHS Pictogram: | ![]() |
Signal Word: | Warning |
Hazard Statements: | H302-H315-H319-H335 |
Precautionary Statements: | P261-P305+P351+P338 |
Name | CaSR ↓ ↑ | Purity | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
NPS-2143 |
++++
Ca(2+) receptor, IC50: 43 nM | 98+% | |||||||||||||||||
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT01100723 | - | Completed | - | - | |
NCT02464072 | Hyperparathyroidism, Secondary | Not Applicable | Active, not recruiting | July 2019 | Brazil ... More >> University of Sao Paulo General Hospital Sao Paulo, SP, Brazil Less << |
NCT01073462 | - | Completed | - | Austria ... More >> Site Reference ID/Investigator# 27447 Graz, Austria, 8010 Site Reference ID/Investigator# 49182 Graz, Austria, 8020 Site Reference ID/Investigator# 27483 Graz, Austria, 80360 Site Reference ID/Investigator# 52742 Graz, Austria, 8052 Site Reference ID/Investigator# 27487 Innsbruck, Austria, 6020 Site Reference ID/Investigator# 36983 Linz, Austria, 4010 Site Reference ID/Investigator# 27484 Linz, Austria, 4020 Site Reference ID/Investigator# 27485 Rottenmann, Austria, 8786 Site Reference ID/Investigator# 27446 Vienna, Austria, 1030 Site Reference ID/Investigator# 53469 Vienna, Austria, 1090 Site Reference ID/Investigator# 27482 Vienna, Austria, 1130 Site Reference ID/Investigator# 10981 Vienna, Austria, 1220 Less << | |
NCT02102204 | Hyperparathyroidism, Secondary | Phase 3 | Completed | - | - |
NCT01717989 | - | Completed | - | - | |
NCT01073462 | - | Completed | - | - | |
NCT02273570 | Hyperparathyroidism, Secondary | Not Applicable | Unknown | March 2017 | Italy ... More >> Azienda Ospedaliera Sant'Anna Recruiting San Fermo della battaglia (CO), Italy, 22020 Contact: Simona Urbano +39.031.585.8947 comitato.etica@hsacomo.org Principal Investigator: Antonio Bellasi, MD Principal Investigator: Claudio Minoretti, MD Less << |
NCT03527511 | - | Recruiting | May 14, 2020 | France ... More >> Service de Néphrologie, Rhumatologie et Dermatologie Pédiatriques - Hôpital Femme Mère Enfant - Bron. Recruiting Bron, France, 69677 Contact: Justine BACCHETTA, Pr 04 27 85 61 30 ext +33 justine.bacchetta@chu-lyon.fr Principal Investigator: Justine BACCHETTA, Pr Sub-Investigator: Bruno RANCHIN, Dr Sub-Investigator: Anne-Laure SELIER-LECLERC, Dr Sub-Investigator: Aurélia BERTHOLET-THOMAS, Dr Sub-Investigator: Elodie CHEYSSAC, Dr Sub-Investigator: Corentin TANNE, Dr Less << | |
NCT02102204 | - | Completed | - | - | |
NCT01421407 | Secondary Hyperparathyroidism ... More >> End Stage Renal Disease Parathyroid Hyperplasia Less << | Not Applicable | Withdrawn | - | Italy ... More >> Ospedale generale regionale "Miulli" Acquaviva delle Fonti, Italy, 70021 Ospedale Maggiore Policlinico Mangiagalli e Regina Elena Milano, Italy, 20122 Spain Hospital Universitario Marquès de Valdecilla Santander, Cantabria, Spain, 39008 Less << |
NCT03603444 | - | Completed | - | Italy ... More >> Azienda Ospedaliero - Universitaria di Modena Modena, Italy, 41124 Less << | |
NCT00656032 | End Stage Renal Disease | Phase 2 | Completed | - | United States, Tennessee ... More >> Vanderbilt University Medical Center Nashville, Tennessee, United States, 37232 Less << |
NCT02440581 | Kidney Failure, Chronic | Not Applicable | Recruiting | June 2020 | United States, Kentucky ... More >> University of Kentucky Recruiting Lexington, Kentucky, United States, 40536 Contact: Nedda Hughes, PA 859-218-1509 nkhugh1@uky.edu Contact: Tara Spach 859-323-2672 tara.spach@uky.edu Less << |
NCT00189501 | - | Completed | - | - | |
NCT00110656 | - | Completed | - | - | |
NCT01011699 | Chronic Renal Failure ... More >> Hemodialysis Less << | Phase 3 | Terminated(Financial problem) | - | France ... More >> Centre Hospitalier Général Soissons, Aisne, France, 02009 Centre Hospitalier Lisieux, Calvados, France, 14100 ALURAD Limoges, Limousin, France, 87042 Centre Hospitalier Universitaire Reims, Marne, France, 51092 Association Régionale Promotion Dialyse à domicile (ARPDD) Reims, Marne, France Association pour le Développement de l'Hémodialyse Hénin-Beaumont, Nord-Pas de Calais, France, 62110 Polyclinique de la Louvière Lille, Nord, France, 59000 CHRU Lille, Nord, France, 59037 Hôpital Victor Provo Roubaix, Nord, France, 59056 Centre Hospitalier Général Valenciennes, Nord, France, 59322 Centre Hospitalier Général Beauvais, Oise, France, 60000 Clinique Saint Côme Compiegne, Oise, France, 60200 Centre Hospitalier Général Creil, Oise, France, 60100 Clinique du Bois Bernard Bois Bernard, Pas de calais, France, 62320 Centre Hospitalier Boulogne sur mer, Pas de calais, France, 62200 Centre Hospital-Universitaire d'Amiens Amiens, Picardie, France, 80054 Clinique de l'Europe Rouen, Seine maritime, France, 76040 Centre Hospitalier Cambrai, France, 59407 Less << |
NCT02525796 | Primary Hyperparathyroidism | Phase 2 Phase 3 | Recruiting | December 2020 | United States, Massachusetts ... More >> Brigham and Women's Hospital Recruiting Boston, Massachusetts, United States, 02115 Contact: Molly Connors 617-732-5186 Less << |
NCT02216656 | Secondary Hyperparathyroidism | Phase 2 | Completed | - | Japan ... More >> For additional information regarding investigative sites for this trial, contact Kyowa Hakko Kirin Tokyo, Japan Less << |
NCT00042432 | - | Completed | - | - | |
NCT01932970 | Hyperparathyroidism, Secondary | Phase 3 | Completed | - | - |
NCT01932970 | - | Completed | - | - | |
NCT00037518 | Hyperparathyroidism ... More >> Parathyroid Neoplasms Less << | Phase 4 | Completed | - | - |
NCT01100723 | Secondary Hyperparathyroidism ... More >> Chronic Kidney Disease Less << | Phase 4 | Completed | - | United States, Virginia ... More >> Lynchburg Nephrology Associates, P.L.L.C. Lynchburg, Virginia, United States, 24501 Less << |
NCT00325104 | Hypercalcemia ... More >> Familial Primary Hyperparathyroidism Less << | Phase 3 | Completed | - | United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less << |
NCT02133404 | Secondary Hyperparathyroidism | Phase 2 | Completed | - | Japan ... More >> Chubu, Japan Chugoku, Japan Kanto, Japan Kyushu, Japan Shikoku, Japan Tohoku, Japan Less << |
NCT00037635 | Secondary Hyperparathyroidism ... More >> End Stage Renal Disease Less << | Phase 3 | Completed | - | - |
NCT00395902 | - | Completed | - | - | |
NCT01599962 | Memory Functions | Phase 2 | Completed | - | Switzerland ... More >> University of Basel, Division of Cognitive Neuroscience Basel, Switzerland, 4055 Less << |
NCT01717989 | - | Completed | - | - | |
NCT00261950 | Secondary Hyperparathyroidism | Phase 2 | Completed | - | - |
NCT01748812 | Osteomalacia | Phase 1 | Terminated | - | United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less << |
NCT00336739 | Healthy | Not Applicable | Completed | - | United States, Massachusetts ... More >> Human Nutrition Research Center on Aging at Tufts University Boston, Massachusetts, United States, 02111 Less << |
NCT01573520 | Hyperparathyroidism ... More >> Chronic Kidney Disease Less << | Phase 4 | Completed | - | Switzerland ... More >> Centre Hospitalier Universitaire Vaudois Lausanne, Switzerland, 1011 Less << |
NCT00042432 | Secondary Hyperparathyroidism ... More >> Chronic Renal Insufficiency Less << | Phase 2 | Completed | - | - |
NCT00042653 | Secondary Hyperparathyroidism ... More >> End Stage Renal Disease Less << | Phase 3 | Completed | - | - |
NCT00132431 | Kidney Disease ... More >> Secondary Hyperparathyroidism Chronic Kidney Disease Less << | Phase 4 | Completed | - | - |
NCT00261950 | - | Completed | - | - | |
NCT00110890 | End Stage Renal Disease | Phase 4 | Completed | - | - |
NCT00113958 | End Stage Renal Disease | Phase 2 | Completed | - | - |
NCT00113945 | End Stage Renal Disease | Phase 2 | Completed | - | - |
NCT00110929 | End Stage Renal Disease | Phase 2 | Completed | - | - |
NCT00110890 | - | Completed | - | - | |
NCT01181531 | Hyperparathyroidism, Secondary | Phase 4 | Completed | - | - |
NCT02227264 | Primary Hyperparathyroidism | Not Applicable | Unknown | December 2016 | Sweden ... More >> Karolinska University Hospital Recruiting Stockholm, Sweden, 171 76 Contact: Inga-Lena Nilsson, Assoc.prof. inga-lena.nilsson@ki.se Less << |
NCT00446329 | Secondary Hyperparathyroidism | Phase 4 | Terminated(due to financial pr... More >>oblems) Less << | - | Greece ... More >> Papageorgiou General Hospital Thessaloniki, Greece, 56403 Less << |
NCT00415584 | Secondary Hyperparathyroidism|... More >>Hypercalcemia Less << | PHASE1|PHASE2 | TERMINATED | 2025-11-09 | Montefiore Medical Center, Bro... More >>nx, New York, 10467, United States Less << |
NCT00094484 | Kidney Disease|Chronic Kidney ... More >>Disease Less << | PHASE3 | COMPLETED | - | - |
NCT00803712 | Chronic Kidney Disease ... More >> Secondary Hyperparathyroidism Less << | Phase 4 | Completed | - | - |
NCT00803712 | - | Completed | - | - | |
NCT00936650 | Hyperparathyroidism, Primary | Phase 2 | Completed | - | - |
NCT00975000 | Chronic Allograft Nephropathy ... More >> Chronic Kidney Disease Chronic Renal Failure Disordered Mineral Metabolism End Stage Renal Disease Hyperparathyroidism Hypophosphatemia Kidney Disease Kidney Transplantation Post Renal Transplantation Less << | Phase 3 | Completed | - | - |
NCT01250405 | Chronic Kidney Disease | Phase 4 | Completed | - | Canada, Quebec ... More >> Karine Marquis Québec, Quebec, Canada, G1R2J6 Less << |
NCT00195936 | Hypophosphatemic Rickets, X-Li... More >>nked Dominant Less << | Phase 1 | Unknown | - | United States, Missouri ... More >> Section of Pediatric Nephrology, Children's Mercy Hospitals and Clinics Recruiting Kansas City, Missouri, United States, 64108 Principal Investigator: Rachel Levy-Olomucki, MD Less << |
NCT01181531 | - | Completed | - | - | |
NCT00975000 | - | Completed | - | - | |
NCT00135304 | Secondary Hyperparathyroidism | Phase 4 | Completed | - | - |
NCT03027557 | Primary Hyperparathyroidism ... More >> Parathyroid Adenoma Parathyroid Hyperplasia Less << | Phase 3 | Enrolling by invitation | March 30, 2019 | Denmark ... More >> Aalborg University Hospital Aalborg, Denmark, 9000 Less << |
NCT01178450 | Secondary Hyperparathyroidism | Phase 4 | Completed | - | Spain ... More >> Hospital Universitari de Bellvitge L'Hospitalet de Llobregat, Barcelone, Spain, 08907 Hospital Clinic de Barcelona Barcelona, Spain, 08036 Less << |
NCT01277510 | - | Terminated(Study was suspended... More >> in agreement between sponsor and FDA due to concerns about the study design after a fatality had occurred in the presence of hypocalcemia.) Less << | - | - | |
NCT00977080 | - | Completed | - | - | |
NCT01277510 | Chronic Kidney Disease ... More >> Hyperparathyroidism Hyperparathyroidism, Secondary Kidney Disease Secondary Hyperparathyroidism Less << | Phase 3 | Terminated(Study was suspended... More >> in agreement between sponsor and FDA due to concerns about the study design after a fatality had occurred in the presence of hypocalcemia.) Less << | - | - |
NCT00928408 | - | Completed | - | - | |
NCT00928408 | - | Completed | - | - | |
NCT00117052 | Secondary Hyperparathyroidism ... More >> End Stage Renal Disease Less << | Phase 3 | Completed | - | - |
NCT00977080 | Chronic Kidney Disease ... More >> Secondary Hyperparathyroidism Hemodialysis Less << | Phase 4 | Completed | - | - |
NCT01447368 | Kidney Failure ... More >> Secondary Hyperparathyroidism Vascular Diseases Less << | Not Applicable | Recruiting | December 2017 | Hong Kong ... More >> Queen Mary Hospital and Tung Wah Hospital Recruiting Hong Kong, Hong Kong, 0000 Contact: Angela YM Wang, MD, PhD 852-22554949 aymwang@hku.hk Principal Investigator: Angela YM Wang, MD, PhD Sub-Investigator: Wai-Kei Lo, FRCP Less << |
NCT00527085 | Renal Osteodystrophy | Phase 2 | Completed | - | - |
NCT00345839 | Secondary Hyperparathyroidism ... More >> Chronic Kidney Disease Less << | Phase 3 | Completed | - | - |
NCT00379899 | - | Completed | - | - | |
NCT01460030 | Parathyroid Carcinoma|Hypercal... More >>cemia|Primary Hyperparathyroidism Less << | PHASE3 | COMPLETED | 2025-02-13 | Sendai, Japan |
NCT01101113 | Secondary Hyperparathyroidism | Phase 4 | Completed | - | Korea, Republic of ... More >> Seoul National University Hospital Seoul, Korea, Korea, Republic of, 110-744 Kyungpook National University Daegu, Korea, Republic of Gil Hospital Incheon, Korea, Republic of Hallym University Sacred Hospital Pyungchon, Korea, Republic of Seoul National University Bundang Hospital Seongnam, Korea, Republic of Eulji University Seoul, Korea, Republic of Samsung Medical Center Seoul, Korea, Republic of Less << |
NCT00379899 | Chronic Kidney Disease ... More >> End Stage Renal Disease Coronary Artery Calcification Vascular Calcification Calcification Cardiovascular Disease Chronic Renal Failure Hyperparathyroidism Kidney Disease Nephrology Secondary Hyperparathyroidism Less << | Phase 4 | Completed | - | - |
NCT01896232 | - | Completed | - | - | |
NCT00936988 | Hyperparathyroidism, Primary | Phase 2 | Completed | - | - |
NCT00975221 | Hyperparathyroidism, Primary ... More >> Hypercalcemia Less << | Phase 3 | Completed | - | - |
NCT00527267 | Hyperparathyroidism | Phase 3 | Completed | - | - |
NCT01896232 | Secondary Hyperparathyroidism ... More >> Chronic Kidney Disease Less << | Phase 3 | Completed | - | - |
NCT01103206 | Parathyroid Hormone Suppressio... More >>n Test With Cinacalcet Less << | Phase 4 | Completed | - | France ... More >> University hospital Rouen, Haute Normandie, France, 76031 Less << |
NCT00975221 | - | Completed | - | - | |
NCT01519037 | Relationship Between Calcimime... More >>tic and the RAAS Less << | Not Applicable | Completed | - | Switzerland ... More >> CHUV, service de néphrologie/hypertension Lausanne, Vaud, Switzerland, 1011 Less << |
NCT03774771 | Primary Hyperparathyroidism | Phase 2 | Completed | - | - |
NCT02138838 | Chronic Kidney Disease, Second... More >>ary Hyperparathyroidism Less << | Phase 3 | Terminated(Sponsor decision) | - | - |
NCT00844740 | Familial Hypophosphatemic Rick... More >>ets Less << | Not Applicable | Unknown | - | United States, Missouri ... More >> Children's Mercy Hospital Kansas City, Missouri, United States, 64108 Less << |
NCT03776058 | Primary Hyperparathyroidism | Phase 2 | Completed | - | - |
NCT02549391 | Secondary Hyperparathyroidism | Phase 2 Phase 3 | Completed | - | Japan ... More >> For additional information regarding investigative sites for this trial, contact Kyowa Hakko Kirin Tokyo, Japan Less << |
NCT02138838 | - | Terminated(Sponsor decision) | - | - | |
NCT00345839 | - | Completed | - | - | |
NCT01143987 | Hyperparathyroidism ... More >> Arterial Stiffness Less << | Phase 4 | Completed | - | Hong Kong ... More >> Prince of Wales Hospital, Chinese University of Hong Kong Shatin, New Territories, Hong Kong, SAR Less << |
NCT00431496 | Anemia Second... More >>ary Hyperparathyroidism Less << | Phase 4 | Completed | - | - |
NCT01011114 | Hypophosphatemia ... More >> Renal Transplant Less << | Not Applicable | Unknown | - | United States, New York ... More >> Montefiore Medical Center Recruiting Bronx, New York, United States, 10467 Principal Investigator: Maria Coco, MD,MS Less << |
NCT00952094 | Healthy | Phase 1 | Completed | - | Korea, Republic of ... More >> Seoul National University Hospital Clinical Trial Center Seoul, Korea, Republic of Less << |
NCT00431496 | - | Completed | - | - | |
NCT02338934 | Secondary Hyperparathyroidism | Phase 4 | Unknown | January 2017 | Malaysia ... More >> Clinical Research Centre, Penang Hospital George Town, Penang, Malaysia, 10990 Penang Hospital Not yet recruiting George Town, Penang, Malaysia, 10990 Contact: Ong Loke Meng, FRCS 00 604 2225333 ext 767 onglm@crc.gov.my Less << |
NCT03123406 | Hyperparathyroidism; Secondary... More >>, Renal Less << | PHASE4 | COMPLETED | 2019-09-06 | Nanjing Jinling Hospital, Nanj... More >>ing, Jiangsu, 210002, China Less << |
NCT02417389 | Hyperparathyroidism, Primary ... More >> Osteoporosis Less << | Phase 4 | Completed | - | Italy ... More >> Istituto Auxologico Italiano IRCCS Milano, Italy, 20145 Less << |
NCT01439867 | - | Terminated(Sponsor decision) | - | - | |
NCT01054079 | Adenocarcinoma of the Prostate... More >> Recurrent Prostate Cancer Less << | Phase 2 | Completed | - | United States, North Carolina ... More >> Wake Forest University Health Sciences Winston-Salem, North Carolina, United States, 27157 Less << |
NCT03299244 | Secondary Hyperparathyroidism ... More >> Chronic Kidney Disease Less << | Phase 3 | Recruiting | November 26, 2019 | - |
NCT01439867 | Chronic Kidney Disease ... More >> Hyperparathyroidism, Secondary Less << | Phase 2 | Terminated(Sponsor decision) | - | - |
NCT02341417 | Secondary Hyperparathyroidism,... More >> Chronic Kidney Disease Less << | Phase 3 | Completed | - | - |
NCT01479088 | Secondary Hyperparathyroidism | PHASE2|PHASE3 | UNKNOWN | 2025-12-13 | U.O. Nefrologia e Dialisi- Osp... More >>edale Giovanni XXIII, Bari, 70100, Italy|U.O. Nefrologia e Dialisi - Istituto di Ricovero e Cura a Carattere Scientifico Giannina Gaslini, Genoa, 16147, Italy|U.O. Nefrologia e Dialisi Pediatrica - Clinica De Marchi, Milan, 20100, Italy|U.O. Nefrologia e Dialisi - Ospedale Santobono, Naples, 80100, Italy|U.O. Nefrologia e Dialisi - Ospedale Bambino Gesù, Rome, 00100, Italy Less << |
NCT01290029 | - | Completed | - | - | |
NCT01290029 | Chronic Kidney Disease ... More >> Hyperparathyroidism, Secondary Secondary Hyperparathyroidism Less << | Phase 1 | Completed | - | United States, California ... More >> Research Site Los Angeles, California, United States, 90095 Research Site San Francisco, California, United States, 94143 United States, Kentucky Research Site Louisville, Kentucky, United States, 40202 United States, Missouri Research Site Kansas City, Missouri, United States, 64108 Germany Research Site Heidelberg, Germany, 69120 United Kingdom Research Site Bristol, United Kingdom, BS2 8BJ Research Site Glasgow, United Kingdom, G3 8SJ Research Site Leeds, United Kingdom, LS1 3EX Research Site Manchester, United Kingdom, M13 9WL Research Site Nottingham, United Kingdom, NG7 2UH Less << |
NCT01054079 | - | Completed | - | - | |
NCT02341417 | - | Completed | - | - |
Tags: 364782-34-3 synthesis path| 364782-34-3 SDS| 364782-34-3 COA| 364782-34-3 purity| 364782-34-3 application| 364782-34-3 NMR| 364782-34-3 COA| 364782-34-3 structure
Precautionary Statements-General | |
Code | Phrase |
P101 | If medical advice is needed,have product container or label at hand. |
P102 | Keep out of reach of children. |
P103 | Read label before use |
Prevention | |
Code | Phrase |
P201 | Obtain special instructions before use. |
P202 | Do not handle until all safety precautions have been read and understood. |
P210 | Keep away from heat/sparks/open flames/hot surfaces. - No smoking. |
P211 | Do not spray on an open flame or other ignition source. |
P220 | Keep/Store away from clothing/combustible materials. |
P221 | Take any precaution to avoid mixing with combustibles |
P222 | Do not allow contact with air. |
P223 | Keep away from any possible contact with water, because of violent reaction and possible flash fire. |
P230 | Keep wetted |
P231 | Handle under inert gas. |
P232 | Protect from moisture. |
P233 | Keep container tightly closed. |
P234 | Keep only in original container. |
P235 | Keep cool |
P240 | Ground/bond container and receiving equipment. |
P241 | Use explosion-proof electrical/ventilating/lighting/equipment. |
P242 | Use only non-sparking tools. |
P243 | Take precautionary measures against static discharge. |
P244 | Keep reduction valves free from grease and oil. |
P250 | Do not subject to grinding/shock/friction. |
P251 | Pressurized container: Do not pierce or burn, even after use. |
P260 | Do not breathe dust/fume/gas/mist/vapours/spray. |
P261 | Avoid breathing dust/fume/gas/mist/vapours/spray. |
P262 | Do not get in eyes, on skin, or on clothing. |
P263 | Avoid contact during pregnancy/while nursing. |
P264 | Wash hands thoroughly after handling. |
P265 | Wash skin thouroughly after handling. |
P270 | Do not eat, drink or smoke when using this product. |
P271 | Use only outdoors or in a well-ventilated area. |
P272 | Contaminated work clothing should not be allowed out of the workplace. |
P273 | Avoid release to the environment. |
P280 | Wear protective gloves/protective clothing/eye protection/face protection. |
P281 | Use personal protective equipment as required. |
P282 | Wear cold insulating gloves/face shield/eye protection. |
P283 | Wear fire/flame resistant/retardant clothing. |
P284 | Wear respiratory protection. |
P285 | In case of inadequate ventilation wear respiratory protection. |
P231 + P232 | Handle under inert gas. Protect from moisture. |
P235 + P410 | Keep cool. Protect from sunlight. |
Response | |
Code | Phrase |
P301 | IF SWALLOWED: |
P304 | IF INHALED: |
P305 | IF IN EYES: |
P306 | IF ON CLOTHING: |
P307 | IF exposed: |
P308 | IF exposed or concerned: |
P309 | IF exposed or if you feel unwell: |
P310 | Immediately call a POISON CENTER or doctor/physician. |
P311 | Call a POISON CENTER or doctor/physician. |
P312 | Call a POISON CENTER or doctor/physician if you feel unwell. |
P313 | Get medical advice/attention. |
P314 | Get medical advice/attention if you feel unwell. |
P315 | Get immediate medical advice/attention. |
P320 | |
P302 + P352 | IF ON SKIN: wash with plenty of soap and water. |
P321 | |
P322 | |
P330 | Rinse mouth. |
P331 | Do NOT induce vomiting. |
P332 | IF SKIN irritation occurs: |
P333 | If skin irritation or rash occurs: |
P334 | Immerse in cool water/wrap n wet bandages. |
P335 | Brush off loose particles from skin. |
P336 | Thaw frosted parts with lukewarm water. Do not rub affected area. |
P337 | If eye irritation persists: |
P338 | Remove contact lenses, if present and easy to do. Continue rinsing. |
P340 | Remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P341 | If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P342 | If experiencing respiratory symptoms: |
P350 | Gently wash with plenty of soap and water. |
P351 | Rinse cautiously with water for several minutes. |
P352 | Wash with plenty of soap and water. |
P353 | Rinse skin with water/shower. |
P360 | Rinse immediately contaminated clothing and skin with plenty of water before removing clothes. |
P361 | Remove/Take off immediately all contaminated clothing. |
P362 | Take off contaminated clothing and wash before reuse. |
P363 | Wash contaminated clothing before reuse. |
P370 | In case of fire: |
P371 | In case of major fire and large quantities: |
P372 | Explosion risk in case of fire. |
P373 | DO NOT fight fire when fire reaches explosives. |
P374 | Fight fire with normal precautions from a reasonable distance. |
P376 | Stop leak if safe to do so. Oxidising gases (section 2.4) 1 |
P377 | Leaking gas fire: Do not extinguish, unless leak can be stopped safely. |
P378 | |
P380 | Evacuate area. |
P381 | Eliminate all ignition sources if safe to do so. |
P390 | Absorb spillage to prevent material damage. |
P391 | Collect spillage. Hazardous to the aquatic environment |
P301 + P310 | IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. |
P301 + P312 | IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. |
P301 + P330 + P331 | IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. |
P302 + P334 | IF ON SKIN: Immerse in cool water/wrap in wet bandages. |
P302 + P350 | IF ON SKIN: Gently wash with plenty of soap and water. |
P303 + P361 + P353 | IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower. |
P304 + P312 | IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell. |
P304 + P340 | IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. |
P304 + P341 | IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P305 + P351 + P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
P306 + P360 | IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes. |
P307 + P311 | IF exposed: call a POISON CENTER or doctor/physician. |
P308 + P313 | IF exposed or concerned: Get medical advice/attention. |
P309 + P311 | IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician. |
P332 + P313 | IF SKIN irritation occurs: Get medical advice/attention. |
P333 + P313 | IF SKIN irritation or rash occurs: Get medical advice/attention. |
P335 + P334 | Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages. |
P337 + P313 | IF eye irritation persists: Get medical advice/attention. |
P342 + P311 | IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician. |
P370 + P376 | In case of fire: Stop leak if safe to Do so. |
P370 + P378 | In case of fire: |
P370 + P380 | In case of fire: Evacuate area. |
P370 + P380 + P375 | In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion. |
P371 + P380 + P375 | In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion. |
Storage | |
Code | Phrase |
P401 | |
P402 | Store in a dry place. |
P403 | Store in a well-ventilated place. |
P404 | Store in a closed container. |
P405 | Store locked up. |
P406 | Store in corrosive resistant/ container with a resistant inner liner. |
P407 | Maintain air gap between stacks/pallets. |
P410 | Protect from sunlight. |
P411 | |
P412 | Do not expose to temperatures exceeding 50 oC/ 122 oF. |
P413 | |
P420 | Store away from other materials. |
P422 | |
P402 + P404 | Store in a dry place. Store in a closed container. |
P403 + P233 | Store in a well-ventilated place. Keep container tightly closed. |
P403 + P235 | Store in a well-ventilated place. Keep cool. |
P410 + P403 | Protect from sunlight. Store in a well-ventilated place. |
P410 + P412 | Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF. |
P411 + P235 | Keep cool. |
Disposal | |
Code | Phrase |
P501 | Dispose of contents/container to ... |
P502 | Refer to manufacturer/supplier for information on recovery/recycling |
Physical hazards | |
Code | Phrase |
H200 | Unstable explosive |
H201 | Explosive; mass explosion hazard |
H202 | Explosive; severe projection hazard |
H203 | Explosive; fire, blast or projection hazard |
H204 | Fire or projection hazard |
H205 | May mass explode in fire |
H220 | Extremely flammable gas |
H221 | Flammable gas |
H222 | Extremely flammable aerosol |
H223 | Flammable aerosol |
H224 | Extremely flammable liquid and vapour |
H225 | Highly flammable liquid and vapour |
H226 | Flammable liquid and vapour |
H227 | Combustible liquid |
H228 | Flammable solid |
H229 | Pressurized container: may burst if heated |
H230 | May react explosively even in the absence of air |
H231 | May react explosively even in the absence of air at elevated pressure and/or temperature |
H240 | Heating may cause an explosion |
H241 | Heating may cause a fire or explosion |
H242 | Heating may cause a fire |
H250 | Catches fire spontaneously if exposed to air |
H251 | Self-heating; may catch fire |
H252 | Self-heating in large quantities; may catch fire |
H260 | In contact with water releases flammable gases which may ignite spontaneously |
H261 | In contact with water releases flammable gas |
H270 | May cause or intensify fire; oxidizer |
H271 | May cause fire or explosion; strong oxidizer |
H272 | May intensify fire; oxidizer |
H280 | Contains gas under pressure; may explode if heated |
H281 | Contains refrigerated gas; may cause cryogenic burns or injury |
H290 | May be corrosive to metals |
Health hazards | |
Code | Phrase |
H300 | Fatal if swallowed |
H301 | Toxic if swallowed |
H302 | Harmful if swallowed |
H303 | May be harmful if swallowed |
H304 | May be fatal if swallowed and enters airways |
H305 | May be harmful if swallowed and enters airways |
H310 | Fatal in contact with skin |
H311 | Toxic in contact with skin |
H312 | Harmful in contact with skin |
H313 | May be harmful in contact with skin |
H314 | Causes severe skin burns and eye damage |
H315 | Causes skin irritation |
H316 | Causes mild skin irritation |
H317 | May cause an allergic skin reaction |
H318 | Causes serious eye damage |
H319 | Causes serious eye irritation |
H320 | Causes eye irritation |
H330 | Fatal if inhaled |
H331 | Toxic if inhaled |
H332 | Harmful if inhaled |
H333 | May be harmful if inhaled |
H334 | May cause allergy or asthma symptoms or breathing difficulties if inhaled |
H335 | May cause respiratory irritation |
H336 | May cause drowsiness or dizziness |
H340 | May cause genetic defects |
H341 | Suspected of causing genetic defects |
H350 | May cause cancer |
H351 | Suspected of causing cancer |
H360 | May damage fertility or the unborn child |
H361 | Suspected of damaging fertility or the unborn child |
H361d | Suspected of damaging the unborn child |
H362 | May cause harm to breast-fed children |
H370 | Causes damage to organs |
H371 | May cause damage to organs |
H372 | Causes damage to organs through prolonged or repeated exposure |
H373 | May cause damage to organs through prolonged or repeated exposure |
Environmental hazards | |
Code | Phrase |
H400 | Very toxic to aquatic life |
H401 | Toxic to aquatic life |
H402 | Harmful to aquatic life |
H410 | Very toxic to aquatic life with long-lasting effects |
H411 | Toxic to aquatic life with long-lasting effects |
H412 | Harmful to aquatic life with long-lasting effects |
H413 | May cause long-lasting harmful effects to aquatic life |
H420 | Harms public health and the environment by destroying ozone in the upper atmosphere |
Sorry,this product has been discontinued.
Home
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :
Total Compounds: mg
The concentration of the dissolution solution you need to prepare is mg/mL